{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:00:48Z","timestamp":1772136048530,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The cardiac lipid panel (CLP) is a novel panel of metabolomic biomarkers that has previously shown to improve the diagnostic and prognostic value for CHF patients. Several prognostic scores have been developed for cardiovascular disease risk, but their use is limited to specific populations and precision is still inadequate. We compared a risk score using the CLP plus NT-proBNP to four commonly used risk scores: The Seattle Heart Failure Model (SHFM), Framingham risk score (FRS), Barcelona bio-HF (BCN Bio-HF) and Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score. We included 280 elderly CHF patients from the Cardiac Insufficiency Bisoprolol Study in Elderly trial. Cox Regression and hierarchical cluster analysis was performed. Integrated area under the curves (IAUC) was used as criterium for comparison. The mean (\n                    <jats:italic>SD<\/jats:italic>\n                    ) follow-up period was 81 (33) months, and 95 (34%) subjects met the primary endpoint. The IAUC for FRS was 0.53, SHFM 0.61, BCN Bio-HF 0.72, MAGGIC 0.68, and CLP 0.78. Subjects were partitioned into three risk clusters: low, moderate, high with the CLP score showing the best ability to group patients into their respective risk cluster. A risk score composed of a novel panel of metabolite biomarkers plus NT-proBNP outperformed other common prognostic scores in predicting 10-year cardiovascular death in elderly ambulatory CHF patients. This approach could improve the clinical risk assessment of CHF patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-87776-w","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T06:05:44Z","timestamp":1618380344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Performance of a cardiac lipid panel compared to four prognostic scores in chronic heart failure"],"prefix":"10.1038","volume":"11","author":[{"given":"Peter","family":"McGranaghan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anshul","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Dirk","family":"D\u00fcngen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muni","family":"Rubens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Appunni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Salami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emir","family":"Veledar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Blaschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Obradovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Loncar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvis","family":"Tahirovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkert","family":"Pieske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias Daniel","family":"Trippel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"issue":"1","key":"87776_CR1","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/CIR.0b013e318245fac5","volume":"125","author":"WG MEMBERS","year":"2012","unstructured":"MEMBERS, W. G. et al. Heart disease and stroke statistics\u25002012 update: A report from the American Heart Association. Circulation 125(1), e2 (2012).","journal-title":"Circulation"},{"issue":"1","key":"87776_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","volume":"8","author":"AL Bui","year":"2011","unstructured":"Bui, A. L., Horwich, T. B. & Fonarow, G. C. Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8(1), 30\u201341 (2011).","journal-title":"Nat. Rev. Cardiol."},{"issue":"11","key":"87776_CR3","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","volume":"113","author":"WC Levy","year":"2006","unstructured":"Levy, W. C. et al. The Seattle Heart Failure Model: Prediction of survival in heart failure. Circulation 113(11), 1424\u20131433 (2006).","journal-title":"Circulation"},{"issue":"19","key":"87776_CR4","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","volume":"34","author":"SJ Pocock","year":"2013","unstructured":"Pocock, S. J. et al. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur. Heart J. 34(19), 1404\u20131413 (2013).","journal-title":"Eur. Heart J."},{"issue":"4","key":"87776_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1001\/jamacardio.2016.5036","volume":"2","author":"LA Allen","year":"2017","unstructured":"Allen, L. A. et al. Use of risk models to predict death in the next year among individual ambulatory patients with heart failure. JAMA Cardiol. 2(4), 435\u2013441 (2017).","journal-title":"JAMA Cardiol."},{"issue":"2","key":"87776_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/ejhf.32","volume":"16","author":"U Sartipy","year":"2014","unstructured":"Sartipy, U. et al. Predicting survival in heart failure: Validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish Heart Failure Registry. Eur. J. Heart Fail. 16(2), 173\u2013179 (2014).","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"87776_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D'Agostino Sr","year":"2008","unstructured":"D\u2019Agostino, R. B. Sr. et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117(6), 743\u2013753 (2008).","journal-title":"Circulation"},{"issue":"1","key":"87776_CR8","doi-asserted-by":"publisher","first-page":"e85466","DOI":"10.1371\/journal.pone.0085466","volume":"9","author":"J Lup\u00f3n","year":"2014","unstructured":"Lup\u00f3n, J. et al. Development of a novel heart failure risk tool: The Barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS ONE 9(1), e85466 (2014).","journal-title":"PLoS ONE"},{"issue":"1","key":"87776_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.recesp.2014.08.009","volume":"68","author":"J Lup\u00f3n","year":"2014","unstructured":"Lup\u00f3n, J. et al. Validation of the Barcelona Bio-Heart Failure Risk Calculator in a cohort from Boston. Rev. Esp. Cardiol. (Engl. ed.) 68(1), 80\u201381 (2014).","journal-title":"Rev. Esp. Cardiol. (Engl. ed.)"},{"key":"87776_CR10","doi-asserted-by":"crossref","unstructured":"Howlett, J. G. Should we perform a heart failure risk score? 4\u20135 (2013).","DOI":"10.1161\/CIRCHEARTFAILURE.112.973172"},{"issue":"1","key":"87776_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCHEARTFAILURE.111.965848","volume":"5","author":"KD Aaronson","year":"2012","unstructured":"Aaronson, K. D. & Cowger, J. Heart failure prognostic models: Why bother?. Cir.c Heart Fail. 5(1), 6\u20139 (2012).","journal-title":"Cir.c Heart Fail."},{"issue":"2","key":"87776_CR12","doi-asserted-by":"publisher","first-page":"e1001381","DOI":"10.1371\/journal.pmed.1001381","volume":"10","author":"EW Steyerberg","year":"2013","unstructured":"Steyerberg, E. W. et al. Prognosis research strategy (PROGRESS) 3: Prognostic model research. PLoS Med. 10(2), e1001381 (2013).","journal-title":"PLoS Med."},{"issue":"1","key":"87776_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.hfc.2017.08.011","volume":"14","author":"CL Albert","year":"2018","unstructured":"Albert, C. L. & Tang, W. H. W. Metabolic Biomarkers in heart failure. Heart Fail. Clin. 14(1), 109\u2013118 (2018).","journal-title":"Heart Fail. Clin."},{"issue":"3","key":"87776_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1161\/CIRCGENETICS.113.000404","volume":"7","author":"AA Gupte","year":"2014","unstructured":"Gupte, A. A. et al. Mechanical unloading promotes myocardial energy recovery in human heart failure. Circ. Cardiovasc. Genet. 7(3), 266\u2013276 (2014).","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"8","key":"87776_CR15","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1161\/CIRCULATIONAHA.115.017545","volume":"133","author":"KC Bedi Jr","year":"2016","unstructured":"Bedi, K. C. Jr. et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133(8), 706\u2013716 (2016).","journal-title":"Circulation"},{"issue":"2","key":"87776_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/1354750X.2020.1716073","volume":"25","author":"P McGranaghan","year":"2020","unstructured":"McGranaghan, P. et al. Predictive value of metabolomic biomarkers for cardiovascular disease risk: A systematic review and meta-analysis. Biomarkers 25(2), 101\u2013111 (2020).","journal-title":"Biomarkers"},{"issue":"15","key":"87776_CR17","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.jacc.2015.02.018","volume":"65","author":"ML Cheng","year":"2015","unstructured":"Cheng, M. L. et al. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. J. Am. Coll. Cardiol. 65(15), 1509\u20131520 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"87776_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jacc.2015.10.079","volume":"67","author":"T Ahmad","year":"2016","unstructured":"Ahmad, T. et al. Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support. J. Am. Coll. Cardiol. 67(3), 291\u2013299 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"18","key":"87776_CR19","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.jacc.2014.02.617","volume":"64","author":"WH Tang","year":"2014","unstructured":"Tang, W. H. et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: Refining the gut hypothesis. J. Am. Coll. Cardiol. 64(18), 1908\u20131914 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"87776_CR20","doi-asserted-by":"publisher","first-page":"e005705","DOI":"10.1161\/JAHA.117.005705","volume":"6","author":"M Ruiz-Canela","year":"2017","unstructured":"Ruiz-Canela, M. et al. Comprehensive metabolomic profiling and incident cardiovascular disease: A systematic review. J. Am. Heart Assoc. 6(10), e005705 (2017).","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"87776_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/CIRCGENETICS.109.852814","volume":"3","author":"SH Shah","year":"2010","unstructured":"Shah, S. H. et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ. Cardiovasc. Genet. 3(2), 207\u2013214 (2010).","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"5","key":"87776_CR22","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ahj.2012.02.005","volume":"163","author":"SH Shah","year":"2012","unstructured":"Shah, S. H. et al. Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am. Heart J. 163(5), 844\u2013850 (2012).","journal-title":"Am. Heart J."},{"issue":"2","key":"87776_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.atherosclerosis.2013.10.029","volume":"232","author":"S Rizza","year":"2014","unstructured":"Rizza, S. et al. Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. Atherosclerosis 232(2), 260\u2013264 (2014).","journal-title":"Atherosclerosis"},{"issue":"1","key":"87776_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ahj.2014.01.019","volume":"168","author":"AA Vaarhorst","year":"2014","unstructured":"Vaarhorst, A. A. et al. A metabolomic profile is associated with the risk of incident coronary heart disease. Am. Heart J. 168(1), 45\u201352 (2014).","journal-title":"Am. Heart J."},{"issue":"6","key":"87776_CR25","doi-asserted-by":"publisher","first-page":"e101219","DOI":"10.1371\/journal.pone.0101219","volume":"9","author":"S Kume","year":"2014","unstructured":"Kume, S. et al. Predictive properties of plasma amino acid profile for cardiovascular disease in patients with type 2 diabetes. PLoS ONE 9(6), e101219 (2014).","journal-title":"PLoS ONE"},{"issue":"4","key":"87776_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/aje\/kwt004","volume":"178","author":"Y Zheng","year":"2013","unstructured":"Zheng, Y. et al. Associations between metabolomic compounds and incident heart failure among African Americans: The ARIC Study. Am. J. Epidemiol. 178(4), 534\u2013542 (2013).","journal-title":"Am. J. Epidemiol."},{"issue":"11","key":"87776_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jchf.2017.07.009","volume":"5","author":"DE Lanfear","year":"2017","unstructured":"Lanfear, D. E. et al. Targeted metabolomic profiling of plasma and survival in heart failure patients. JACC Heart Fail. 5(11), 823\u2013832 (2017).","journal-title":"JACC Heart Fail."},{"issue":"9","key":"87776_CR28","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.114.013116","volume":"131","author":"P Wurtz","year":"2015","unstructured":"Wurtz, P. et al. Metabolite profiling and cardiovascular event risk: A prospective study of 3 population-based cohorts. Circulation 131(9), 774\u2013785 (2015).","journal-title":"Circulation"},{"issue":"1","key":"87776_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1373\/clinchem.2016.257279","volume":"63","author":"M Mueller-Hennessen","year":"2017","unstructured":"Mueller-Hennessen, M. et al. A novel lipid biomarker panel for the detection of heart failure with reduced ejection fraction. Clin. Chem. 63(1), 267\u2013277 (2017).","journal-title":"Clin. Chem."},{"key":"87776_CR30","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1002\/ehf2.12928","volume":"7","author":"P McGranaghan","year":"2020","unstructured":"McGranaghan, P. et al. Incremental prognostic value of a novel metabolite-based biomarker score in congestive heart failure patients. ESC Heart Fail. 7, 3029\u20133039 (2020).","journal-title":"ESC Heart Fail."},{"issue":"11","key":"87776_CR31","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1161\/STROKEAHA.112.668319","volume":"43","author":"A Towfighi","year":"2012","unstructured":"Towfighi, A., Markovic, D. & Ovbiagele, B. Utility of Framingham coronary heart disease risk score for predicting cardiac risk after stroke. Stroke 43(11), 2942\u20132947 (2012).","journal-title":"Stroke"},{"issue":"3","key":"87776_CR32","doi-asserted-by":"publisher","first-page":"e60008","DOI":"10.1371\/journal.pone.0060008","volume":"8","author":"SC Chen","year":"2013","unstructured":"Chen, S. C. et al. Framingham risk score with cardiovascular events in chronic kidney disease. PLoS ONE 8(3), e60008 (2013).","journal-title":"PLoS ONE"},{"issue":"172","key":"87776_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ahj.2015.10.023","volume":"1","author":"JD Sara","year":"2016","unstructured":"Sara, J. D. et al. Utility of the Framingham Risk Score in predicting secondary events in patients following percutaneous coronary intervention: A time-trend analysis. Am. Heart J. 1(172), 115\u2013128 (2016).","journal-title":"Am. Heart J."},{"issue":"6","key":"87776_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/hrt.2005.071233","volume":"92","author":"M Weber","year":"2006","unstructured":"Weber, M. & Hamm, C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 92(6), 843\u2013849 (2006).","journal-title":"Heart"},{"issue":"22","key":"87776_CR35","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.jacc.2016.10.001","volume":"68","author":"PM McKie","year":"2016","unstructured":"McKie, P. M. & Burnett, J. C. Jr. NT-proBNP: The gold standard biomarker in heart failure. J. Am. Coll. Cardiol. 68(22), 2437\u20132439 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"87776_CR36","doi-asserted-by":"publisher","first-page":"e004312","DOI":"10.1161\/CIRCHEARTFAILURE.117.004312","volume":"11","author":"R Scherzer","year":"2018","unstructured":"Scherzer, R. et al. Association of biomarker clusters with cardiac phenotypes and mortality in patients With HIV infection. Circ. Heart Fail. 11(4), e004312 (2018).","journal-title":"Circ. Heart Fail."},{"issue":"17","key":"87776_CR37","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jacc.2014.07.979","volume":"64","author":"T Ahmad","year":"2014","unstructured":"Ahmad, T. et al. Clinical implications of chronic heart failure phenotypes defined by cluster analysis. J. Am. Coll. Cardiol. 64(17), 1765\u20131774 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"87776_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2011.01.083","volume":"155","author":"J Jensen","year":"2012","unstructured":"Jensen, J., Ma, L. P., Bjurman, C., Hammarsten, O. & Fu, M. L. Prognostic values of NTpro BNP\/BNP ratio in comparison with NTpro BNP or BNP alone in elderly patients with chronic heart failure in a 2-year follow up. Int. J. Cardiol. 155(1), 1\u20135 (2012).","journal-title":"Int. J. Cardiol."},{"issue":"9","key":"87776_CR39","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ejheart.2008.07.014","volume":"10","author":"A Maisel","year":"2008","unstructured":"Maisel, A. et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur. J. Heart Fail. 10(9), 824\u2013839 (2008).","journal-title":"Eur. J. Heart Fail."},{"key":"87776_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12944-015-0053-y","volume":"14","author":"S Borodzicz","year":"2015","unstructured":"Borodzicz, S., Czarzasta, K., Kuch, M. & Cudnoch-Jedrzejewska, A. Sphingolipids in cardiovascular diseases and metabolic disorders. Lipids Health Dis. 14, 55 (2015).","journal-title":"Lipids Health Dis."},{"issue":"11","key":"87776_CR41","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do, R. et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 45(11), 1345\u20131352 (2013).","journal-title":"Nat. Genet."},{"issue":"1","key":"87776_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000315104","volume":"26","author":"X Li","year":"2010","unstructured":"Li, X., Becker, K. A. & Zhang, Y. Ceramide in redox signaling and cardiovascular diseases. Cell. Physiol. Biochem. 26(1), 41\u201348 (2010).","journal-title":"Cell. Physiol. Biochem."},{"issue":"7","key":"87776_CR43","doi-asserted-by":"publisher","first-page":"e005708","DOI":"10.1161\/CIRCHEARTFAILURE.118.005708","volume":"12","author":"RN Lemaitre","year":"2019","unstructured":"Lemaitre, R. N. et al. Plasma ceramides and sphingomyelins in relation to heart failure risk: The Cardiovascular Health Study. Circul. Heart Fail. 12(7), e005708 (2019).","journal-title":"Circul. Heart Fail."},{"issue":"1","key":"87776_CR44","doi-asserted-by":"publisher","first-page":"e85724","DOI":"10.1371\/journal.pone.0085724","volume":"9","author":"A Sigruener","year":"2014","unstructured":"Sigruener, A. et al. Glycerophospholipid and sphingolipid species and mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. PLoS ONE 9(1), e85724 (2014).","journal-title":"PLoS ONE"},{"issue":"10","key":"87776_CR45","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1016\/j.bbamem.2012.02.002","volume":"1818","author":"A Reis","year":"2012","unstructured":"Reis, A. & Spickett, C. M. Chemistry of phospholipid oxidation. Biochim. Biophys. Acta (BBA) Biomembr. 1818(10), 2374\u20132387 (2012).","journal-title":"Biochim. Biophys. Acta (BBA) Biomembr."},{"issue":"23","key":"87776_CR46","doi-asserted-by":"publisher","first-page":"101119","DOI":"10.1016\/j.redox.2019.101119","volume":"1","author":"E Gianazza","year":"2019","unstructured":"Gianazza, E., Brioschi, M., Fernandez, A. M. & Banfi, C. Lipoxidation in cardiovascular diseases. Redox Biol. 1(23), 101119 (2019).","journal-title":"Redox Biol."},{"issue":"5","key":"87776_CR47","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11745-012-3654-5","volume":"47","author":"SE Norris","year":"2012","unstructured":"Norris, S. E., Mitchell, T. W. & Else, P. L. Phospholipid peroxidation: Lack of effect of fatty acid pairing. Lipids 47(5), 451\u2013460 (2012).","journal-title":"Lipids"},{"issue":"2","key":"87776_CR48","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1021\/tx600331s","volume":"20","author":"KA Tallman","year":"2007","unstructured":"Tallman, K. A. et al. Phospholipid\u2212protein adducts of lipid peroxidation: Synthesis and study of new biotinylated phosphatidylcholines. Chem. Res. Toxicol. 20(2), 227\u2013234 (2007).","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"87776_CR49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3945\/ajcn.116.131771","volume":"104","author":"Y Zheng","year":"2016","unstructured":"Zheng, Y. et al. Dietary phosphatidylcholine and risk of all-cause and cardiovascular-specific mortality among US women and men. Am. J. Clin. Nutr. 104(1), 173\u2013180 (2016).","journal-title":"Am. J. Clin. Nutr."},{"issue":"26","key":"87776_CR50","doi-asserted-by":"publisher","first-page":"101292","DOI":"10.1016\/j.redox.2019.101292","volume":"1","author":"M Wallert","year":"2019","unstructured":"Wallert, M. et al. \u03b1-Tocopherol preserves cardiac function by reducing oxidative stress and inflammation in ischemia\/reperfusion injury. Redox Biol. 1(26), 101292 (2019).","journal-title":"Redox Biol."},{"issue":"1","key":"87776_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0851-z","volume":"18","author":"X Ye","year":"2019","unstructured":"Ye, X., Kong, W., Zafar, M. I. & Chen, L. L. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovasc. Diabetol. 18(1), 1 (2019).","journal-title":"Cardiovasc. Diabetol."},{"issue":"20","key":"87776_CR52","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","volume":"123","author":"M Miller","year":"2011","unstructured":"Miller, M. et al. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 123(20), 2292\u20132333 (2011).","journal-title":"Circulation"},{"issue":"3","key":"87776_CR53","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.metabol.2003.10.011","volume":"53","author":"AJ Tremblay","year":"2004","unstructured":"Tremblay, A. J. et al. Associations between the fatty acid content of triglyceride, visceral adipose tissue accumulation, and components of the insulin resistance syndrome. Metabolism 53(3), 310\u2013317 (2004).","journal-title":"Metabolism"},{"issue":"4","key":"87776_CR54","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s00125-009-1282-2","volume":"52","author":"A Kotronen","year":"2009","unstructured":"Kotronen, A. et al. Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 52(4), 684\u2013690 (2009).","journal-title":"Diabetologia"},{"issue":"9","key":"87776_CR55","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jchf.2018.06.001","volume":"6","author":"A Bay\u00e9s-Gen\u00eds","year":"2018","unstructured":"Bay\u00e9s-Gen\u00eds, A. & Lup\u00f3n, J. The Barcelona Bio-HF calculator: A contemporary web-based heart failure risk score. JACC Heart Fail. 6(9), 808\u2013810 (2018).","journal-title":"JACC Heart Fail."},{"issue":"9","key":"87776_CR56","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s00392-008-0681-6","volume":"97","author":"HD Dungen","year":"2008","unstructured":"Dungen, H. D. et al. Bisoprolol vs. carvedilol in elderly patients with heart failure: Rationale and design of the CIBIS-ELD trial. Clin. Res. Cardiol. 97(9), 578\u2013586 (2008).","journal-title":"Clin. Res. Cardiol."},{"issue":"6","key":"87776_CR57","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/eurjhf\/hfr020","volume":"13","author":"HD Dungen","year":"2011","unstructured":"Dungen, H. D. et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: The CIBIS-ELD trial. Eur. J. Heart Fail. 13(6), 670\u2013680 (2011).","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"87776_CR58","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1373\/clinchem.2013.211979","volume":"60","author":"B Kamlage","year":"2014","unstructured":"Kamlage, B. et al. Quality markers addressing preanalytical variations of blood and plasma processing identified by broad and targeted metabolite profiling. Clin. Chem. 60(2), 399\u2013412 (2014).","journal-title":"Clin. Chem."},{"key":"87776_CR59","unstructured":"Kamlage, B., Schmitz, O., Kastler, J., Catchpole, G., Dostler, M., Liebenberg, V., inventors; Metanomics Health GmbH, assignee. Means and Methods for Assessing the Quality of a Biological Sample. United States patent application US 14\/767,059. (2016)."},{"issue":"5402","key":"87776_CR60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/bmj.2.5402.177","volume":"2","author":"PP Rickham","year":"1964","unstructured":"Rickham, P. P. Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki. Br. Med. J. 2(5402), 177 (1964).","journal-title":"Br. Med. J."},{"issue":"1","key":"87776_CR61","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer 3(1), 32\u201335 (1950).","journal-title":"Cancer"},{"issue":"18","key":"87776_CR62","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","volume":"247","author":"FE Harrell","year":"1982","unstructured":"Harrell, F. E., Califf, R. M., Pryor, D. B., Lee, K. L. & Rosati, R. A. Evaluating the yield of medical tests. JAMA 247(18), 2543\u20132546 (1982).","journal-title":"JAMA"},{"issue":"10","key":"87776_CR63","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/sim.4154","volume":"30","author":"H Uno","year":"2011","unstructured":"Uno, H., Cai, T., Pencina, M. J., D\u2019Agostino, R. B. & Wei, L. J. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat. Med. 30(10), 1105\u20131117 (2011).","journal-title":"Stat. Med."},{"key":"87776_CR64","unstructured":"SAS software, Version 9.4 of the SAS System for Windows. Copyright 2019 SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA. http:\/\/support.sas.com."},{"key":"87776_CR65","unstructured":"StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC. http:\/\/stata.com (2019)."},{"key":"87776_CR66","unstructured":"JMP, Version 14. SAS Institute Inc., Cary, NC, 1989\u20132019. http:\/\/jmp.com."},{"key":"87776_CR67","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/ (2019)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87776-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87776-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87776-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T01:29:00Z","timestamp":1675128540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87776-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["87776"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-87776-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-131137\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"assertion":[{"value":"18 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8164"}}